US Patent

US9532971 — Low-dose doxepin formulations and methods of making and using the same

Formulation · Assigned to Pernix Sleep Inc · Expires 2029-06-01 · 3y remaining

Vulnerability score 48/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects low-dose oral doxepin pharmaceutical formulations used to promote sleep.

USPTO Abstract

The invention disclosed herein generally relates to low-dose oral doxepin pharmaceutical formulations and the use of these formulations to promote sleep.

Drugs covered by this patent

doxepin-hydrochloride (DOXEPIN HYDROCHLORIDE)

Patent Metadata

Patent number: US9532971
Jurisdiction: US
Classification: Formulation
Expires: 2029-06-01
Drug substance claim: No
Drug product claim: Yes
Assignee: Pernix Sleep Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.